News

The results demonstrated an excellent safety profile and potent IgG reduction capability. The full study will be presented at an upcoming international conference. Based on the results of

Committed to advancing the research and development process and clinical utility of biopharmaceutical companies’ novel biomarker-driven oncology drug, Genetron Health has already formed partnerships with dozens of leading

Claimed to be the first FDA-approved intravenous (IV) treatment for migraine prevention, the Vyepti will be available from April and the recommended dose is 100mg for every three

This procedure was performed at the NHS St James’s University Hospital in Leeds (United Kingdom). Dr. Adel Samson, Academic Medical Oncologist at The Leeds Teaching Hospitals NHS Trust

“These designations for FORMA’s lead clinical asset underscore the FDA’s continued recognition of the needs of patients with SCD,” said Frank Lee, chief executive officer of FORMA Therapeutics.

As per terms of the deal, Immatics will secure an upfront payment of up to $50m from GSK for two initial programmes. Immatics has an option to secure

The FDA is expected to make a decision on approval by June 19, 2020. “In the IMpower110 study, Tecentriq alone demonstrated a significant improvement in overall survival compared

DSM developed and patented a method to produce a highly pure form of the API. Included in the acquisition are patents, trademarks, trade secret manufacturing processes, analytical methods,

The breakthrough therapy status enables Padcev plus Keytruda combination to treat patients with unresectable locally advanced or metastatic urothelial cancer who are unable to receive cisplatin-based chemotherapy in